[Click E-Stock] "Metabiomed Boosts Profitability with High Value-Added Product Mix...Expands New Businesses and Shareholder Returns"

Metabiomed, a company specializing in biodegradable polymer materials, is boosting its profitability by shifting its business structure from a focus on general-purpose products to high value-added products. The company is expanding new business areas such as sports medicine and biodegradable polymer fillers, while also strengthening shareholder returns through dividend increases and share buyback cancellations.

On September 8, the independent research firm ARIS released a corporate analysis report on Metabiomed, highlighting the improvement in product mix based on biopolymer material technology as a key investment point.

Metabiomed's competitiveness lies in its vertically integrated system, which covers everything from the synthesis of biopolymers—the raw materials for suture threads—to fiber spinning. With its in-house capabilities for producing and processing polymer materials, the company is expanding its business beyond its existing suture business to high value-added new areas such as fillers and sports medicine.

The improvement in profitability is evident. On a consolidated basis, the operating margin has risen for three consecutive quarters: from 11.2% in the fourth quarter of last year, to 19.9% in the first quarter of this year, and to 23.2% in the second quarter. In the second quarter of this year, revenue reached 26.9 billion won and operating profit was 6.2 billion won, representing quarter-on-quarter increases of 10.5% and 29.2%, respectively.

ARIS attributed this earnings improvement to increased sales of high value-added products and new items, as well as improved production efficiency.

The company continues to secure a stable profit base in its existing businesses. In the dental segment, 'CeraSeal,' a bioceramic sealer used in the restoration process after nerve treatment, has established itself as a major product. According to the company, CeraSeal alone generated revenue of 12.5 billion won last year.

In the suture business, the company supplies semi-finished biodegradable suture threads to global finished product manufacturers. The biopolymer material technology accumulated in this process is expected to serve as a foundation for further expansion into new business sectors.

Sports medicine is seen as a new growth driver. Metabiomed has expanded its orthopedic product portfolio by launching 'anchors,' which are soft tissue fixation devices used for repairing ligament and muscle tears. The company plans to expand its product lineup by developing both biodegradable and non-biodegradable products.

The company is also preparing to enter the filler business. Metabiomed is pursuing a new business in biodegradable polymer fillers using biocompatible synthetic polymers such as PLA and PDO. The strategy is to expand into high value-added medical and aesthetic fields by leveraging its existing biopolymer material technology.

The company is also strengthening its shareholder return policy. Metabiomed raised its year-end dividend per share from 30 won in 2024 to 105 won last year. After adding a mid-year dividend clause to its articles of incorporation, the company distributed an interim dividend of 55 won per share this past June.

The company is also carrying out share cancellation. In March, Metabiomed performed a profit-based cancellation of 922,856 shares. Of the 770,000 shares acquired this year, some have already been paid as stock compensation to employees, and the remainder is set to be cancelled by the end of the year.

ARIS emphasized that the stable cash flow from the existing dental and suture businesses supports investment in new businesses. If both profitability in existing businesses and growth in new businesses are strengthened simultaneously, there is potential for long-term corporate value appreciation.

A Metabiomed representative stated, "The proprietary technologies and stable cash flow we have accumulated in the dental and suture businesses serve as the basis for investing in new business ventures. By simultaneously pushing forward a shift to high value-added products and enhancing shareholder returns, we aim to grow our performance and corporate value together."

Meanwhile, in August, Metabiomed participated in 'CPHI Korea 2026', showcasing biopolymer raw materials such as PGLA, PLLA, and PDLLA, as well as skin boosters, as part of its efforts to expand its materials business. Building upon technical expertise secured in existing medical materials operations, the company is projected to continue its strategy of increasing the share of high value-added products and new businesses.

This content was produced with the assistance of AI translation services.